Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULDOSA (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18. “With the consecutive approvals in the United States and Europe, IMULDOSA is now one step closer to entering the global pharmaceutical market. We will continue to dedicate our efforts to ensure that IMULDOSA establishes a strong presence in the market, providing an effective treatment...